ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Efficacy of losartan vs. atenolol for the prevention of aortic dilation in Marfan syndrome: a randomized clinical trial

Sunday, March 27, 2016

Submitted by

J. Rafael Sadaba

Source

Source Name: European Heart Journal

Source URL: http://eurheartj.oxfordjournals.org/content/37/12/978.abstract?etoc

Author(s)

Forteza A, Evangelista A, Sánchez V, Teixidó-Turà G, Sanz P, Gutiérrez L, Gracia T, Centeno J, Rodríguez-Palomares J, Rufilanchas JJ, Cortina J, Ferreira-González I, García-Dorado D.

Therapy with b-blockers has shown a beneficial effect in reducing aortic dilation progression and has been proposed as the standard treatment for Marfan´s syndrome (MFS). However, angiotensin II-receptor blockers are emerging as potential alternatives to b-blockers. In this manuscript the authors describe the results of a phase IIIb randomized, parallel, double-blind study of 140 MFS patients comparing the effect of losartan and atenolol. Primary end-points were changes in aortic root and ascending aorta diameter indexed by body surface area (BSA) on MRI after 36 months of treatment. Results showed no differences in the effects of losartan and atenolol on changes in aortic root and ascending aorta diameters in MFS patients.